Access requires that you are 21 years of age or older. Products are for laboratory and research use only — not for human or veterinary use, consumption, or clinical application.
NAD+ reference material, supplied as a lyophilized powder in a sealed vial for in-vitro laboratory research and analytical method development. Each fill size is a separate SKU. Lot and COA records are shown when assigned.
This listing is a research chemical / reference material. No therapeutic, preventive, or diagnostic claims are made or implied. The storefront displays only approved analytical characterization data released through its public report records.
NAD+ is a coenzyme in cellular redox reactions and nutrient-sensing pathways — not a peptide. Endogenous, produced through the cellular salvage biosynthesis pathway.
Acts as a cofactor for sirtuins, mitochondrial function, and DNA repair enzymes that consume NAD+. Vectra makes no claim as to mechanism or effect.
A PRISMA systematic review covered 113 studies — 33 human, 80 rodent — from January 2010 to October 2025. It found clear target engagement from oral precursors: NAD+ levels rise. Functional, metabolic and vascular outcomes were often null. A separate tolerability pilot compared intravenous NAD+ against intravenous nicotinamide riboside.
Studied in sirtuin activity, mitochondrial function, and DNA repair. Vectra supplies it as a reference material for in-vitro laboratory research and analytical method development only.
No formal evidence rating is established. The pattern in the literature is a gap between biomarker and function: at the regulatory-permitted 300 mg/day precursor dose, blood NAD+ rose 40–59% while muscle NAD+ was not measurably raised. Raising a blood level is not the same as producing an effect.
Oral precursors are generally described as safe and tolerable. Intravenous NAD+ was associated with more gastrointestinal symptoms, tachycardia and chest pressure than intravenous nicotinamide riboside, and required a longer infusion time. No long-term outcome data for intravenous NAD+ was located.
Our sources carry no CAS number, formula, molecular weight, or storage data for NAD+.
Direct NAD+ has no FDA-approved therapeutic indication. No therapeutic, preventive, or diagnostic claims are made or implied.
These are the specific, documented failure modes that lot-level third-party analysis addresses. A report reachable from the lot code printed on the vial — without asking the seller for it — is the only document that answers 'is this vial what the label says'. That is why every Vectra vial carries a QR code resolving to its own lot's published report.
Findings reported by commercial testing providers. Each names its source; none is registry- or peer-review-grade, so read them as a documented pattern rather than established prevalence.
Yes, and altered certificates have been reported in this market at material rates — see the testing findings above. Three properties make a report hard to fake:
Peptide identity data in the vendor market is often wrong in ways that are hard to see. Near-identical compounds get their CAS numbers, residue ranges, formulas and molecular weights swapped. A certificate can be internally consistent and still describe a different molecule than the label names. Most commercial peptide material ships as an acetate salt, not free base. The two forms have different measured masses, so a figure quoted against the wrong one will not reconcile. A report that does not state which form it assayed cannot be checked at all.
The standard our own reports are built to meet:
FDA has acted in this market between 2024 and 2026. Actions include a civil forfeiture over $1.7 million against a compounding operation, several rounds of warning letters to peptide vendors, and more than thirty letters in March 2026 concerning compounded GLP-1 products.
Buyers here increasingly compare document trail, not price.
Compatibility does not assert current availability. No preparation, ratio, or protocol guidance renders here.